BRISBANE, Calif., May 19, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) will conduct a live webcast of its 2011 Analyst Day presentations on Thursday, May 26, 2011, from 8:30 a.m. 11:30 a.m. EDT in New York. Presentations by InterMune’s executive management team will provide an overview of the company’s vision, strategy and a comprehensive update of InterMune’s commercial and scientific plans. The company also will provide details on its preparations to launch Esbriet® (pirfenidone) for the treatment of adult patients with mild to moderate idiopathic pulmonary fibrosis (IPF) in Europe and on ASCEND, a new Phase 3 study of pirfenidone, including study design, scientific rationale and guidance on important study and NDA resubmission milestones.
To access the webcast of the Analyst Day presentations, investors and other interested parties may log on to the investor relations page of InterMune’s corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease. The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
SOURCE InterMune, Inc.
